Non-Metastatic Pelvic Ewing's Sarcoma: Oncologic outcomes and evaluation of prognostic factors

Abstract

We are reporting our experience on patients with pelvic Ewing's Sarcoma treated in our unit. We retrospectively reviewed a series of patients with non-metastatic pelvic Ewing's sarcoma treated between 1977 and 2009. Patients were classifed into three groups according to the local treatment received: Group 1. radiotherapy-chemo; Group 2. surgery-chemo and Group 3. radiotherapy-surgery-chemo. Recurrence free and overall survival rates were calculated using the Kaplan-Meier method. In?uence of various factors (age at diagnosis, gender, tumour site and size, chemotherapy response, surgical margins and type of treatment) on survival was assessed with a logistic regression model. A total of 85 patients were treated with a mean follow-up of 65.8 months and mean tumour volume of 435ml. The 5-year survival for all patients was 40.7% decreased to 36.2% at 10 years. A signifcant prognostic factor identifed was chemotherapy response only. There was a trend for improved survival and local control rates for patients who had chemotherapy and surgery and the results were apparent for all tumours irrespective of size but not statistically signifcant. Currently, the optimal management of pelvic Ewing's sarcoma is controversial but our study shows a trend for improved survival for patients treated with chemotherapy and surgery. © 2016, Acta Orthopedica Belgica.